These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30062975)

  • 1. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
    Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-κB signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
    Kishore T KK; Ganugula R; Gade DR; Reddy GB; Nagini S
    Tumour Biol; 2016 Feb; 37(2):2083-93. PubMed ID: 26342697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1/PI3K/Akt Signalling.
    Nivetha R; Arvindh S; Baba AB; Gade DR; Gopal G; K C; Reddy KP; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2022; 22(14):2619-2636. PubMed ID: 35125086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer.
    Sophia J; Kowshik J; Dwivedi A; Bhutia SK; Manavathi B; Mishra R; Nagini S
    Cell Death Dis; 2018 Oct; 9(11):1087. PubMed ID: 30352996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting the PI3K/Akt, NF-κB signalling pathways with syringic acid for attenuating the development of oral squamous cell carcinoma cells SCC131.
    Velu P; Vijayalakshmi A; Vinothkumar V
    J Pharm Pharmacol; 2020 Nov; 72(11):1595-1606. PubMed ID: 32790092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.
    El Gamal H; Eid AH; Munusamy S
    Biomed Res Int; 2017; 2017():5903105. PubMed ID: 28386557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
    Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
    J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-κΒ/STAT3 signalling axis in oral squamous cell carcinoma models.
    Kowshik J; Nivetha R; Ranjani S; Venkatesan P; Selvamuthukumar S; Veeravarmal V; Nagini S
    IUBMB Life; 2019 Oct; 71(10):1595-1610. PubMed ID: 31251469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3β in a hamster model of oral oncogenesis.
    Sophia J; Kiran Kishore T K; Kowshik J; Mishra R; Nagini S
    Sci Rep; 2016 Feb; 6():22192. PubMed ID: 26902162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
    Banala VT; Urandur S; Sharma S; Sharma M; Shukla RP; Marwaha D; Gautam S; Dwivedi M; Mishra PR
    Biomater Sci; 2019 Jun; 7(7):2889-2906. PubMed ID: 31086900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.
    Wang X; Yu F; Zheng WQ
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):294-303. PubMed ID: 31389594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway.
    Subramani R; Gonzalez E; Nandy SB; Arumugam A; Camacho F; Medel J; Alabi D; Lakshmanaswamy R
    Oncotarget; 2017 Feb; 8(7):10891-10904. PubMed ID: 26988754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
    Ramana KV; Tammali R; Srivastava SK
    Mol Cancer Ther; 2010 Apr; 9(4):813-24. PubMed ID: 20354121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways.
    Zeng KW; Li J; Dong X; Wang YH; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):159-71. PubMed ID: 24021941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
    Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
    Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
    Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
    Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
    Huang Z; Hong Q; Zhang X; Xiao W; Wang L; Cui S; Feng Z; Lv Y; Cai G; Chen X; Wu D
    Cell Commun Signal; 2017 Jan; 15(1):3. PubMed ID: 28057038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
    Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
    Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.